Clinical Trial Update: Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of an investigational Tarix Pharmaceuticals agent to reduce chemotherapy-induced thrombocytopenia in patients with ovarian, fallopian tube, or pri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Tarix investigational thrombocytopenia-reduction agent

Snippet

Sponsor: Tarix Pharmaceuticals | Conditions: Thrombocytopenia, Neutropenia | Phase 2 | Status: COMPLETED | Results posted: 2013-06-07